Inventor · disambiguated record
Julia Grigorieva
Also filed as: GRIGORIEVA JULIA
23 granted patents·6 pending applications·314 citations·filing 2006–2021
96Inventor score
Top patents by PatentIndex Score
29 records- 0198US7736905B2Method and system for determining whether a drug will be effective on a patient with a diseaseBIODESIX INC·Filed 2006·Granted Jun 15, 2010·72 cites·18 claims
- 0296US8718996B2Method for predicting whether a cancer patient will not benefit from platinum-based chemotherapy agentsBIODESIX INC·Filed 2013·Granted May 6, 2014·19 cites·10 claims
- 0395US7906342B2Monitoring treatment of cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samplesBIODESIX INC·Filed 2009·Granted Mar 15, 2011·23 cites·3 claims
- 0495US7879620B2Method and system for determining whether a drug will be effective on a patient with a diseaseBIODESIX INC·Filed 2010·Granted Feb 1, 2011·24 cites·8 claims
- 0595US7858389B2Selection of non-small-cell lung cancer patients for treatment with monoclonal antibody drugs targeting EGFR pathwayBIODESIX INC·Filed 2009·Granted Dec 28, 2010·30 cites·4 claims
- 0693US10007766B2Predictive test for melanoma patient benefit from antibody drug blocking ligand activation of the T-cell programmed cell death 1 (PD-1) checkpoint protein and classifier development methodsBIODESIX INC·Filed 2016·Granted Jun 26, 2018·9 cites·8 claims
- 0793US8119417B2Monitoring treatment of head and neck cancer patients with drugs EGFR pathway using mass spectrometry of patient samplesROEDER HEINRICH·Filed 2011·Granted Feb 21, 2012·8 cites·4 claims
- 0893US8119418B2Monitoring treatment of colorectal cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samplesROEDER HEINRICH·Filed 2011·Granted Feb 21, 2012·8 cites·4 claims
- 0992US10217620B2Early detection of hepatocellular carcinoma in high risk populations using MALDI-TOF mass spectrometryBIODESIX INC·Filed 2018·Granted Feb 26, 2019·6 cites·10 claims
- 1092US8586379B2Monitoring treatment of colorectal cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samplesROEDER HEINRICH·Filed 2011·Granted Nov 19, 2013·6 cites·4 claims
- 1192US8586380B2Monitoring treatment of head and neck cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samplesROEDER HEINRICH·Filed 2011·Granted Nov 19, 2013·6 cites·4 claims
- 1292US8097469B2Method and system for determining whether a drug will be effective on a patient with a diseaseROEDER HEINRICH·Filed 2010·Granted Jan 17, 2012·15 cites·17 claims
- 1392US7858390B2Selection of colorectal cancer patients for treatment with drugs targeting EGFR pathwayBIODESIX INC·Filed 2009·Granted Dec 28, 2010·26 cites·7 claims
- 1491US10037874B2Early detection of hepatocellular carcinoma in high risk populations using MALDI-TOF mass spectrometryBIODESIX INC·Filed 2015·Granted Jul 31, 2018·6 cites·9 claims
- 1590US7867775B2Selection of head and neck cancer patients for treatment with drugs targeting EGFR pathwayBIODESIX INC·Filed 2009·Granted Jan 11, 2011·21 cites·5 claims
- 1689US8914238B2Method for predicting breast cancer patient response to endocrine therapyRÖDER JOANNA·Filed 2012·Granted Dec 16, 2014·12 cites·7 claims
- 1787US9254120B2Method for predicting breast cancer patient response to combination therapyBIODESIX INC·Filed 2013·Granted Feb 9, 2016·5 cites·8 claims
- 1886US9152758B2Method and system for determining whether a drug will be effective on a patient with a diseaseRÖDER HEINRICH·Filed 2011·Granted Oct 6, 2015·7 cites·2 claims
- 1985US10950348B2Predictive test for patient benefit from antibody drug blocking ligand activation of the T-cell programmed cell death 1 (PD-1) checkpoint protein and classifier development methodsBIODESIX INC·Filed 2018·Granted Mar 16, 2021·2 cites·11 claims
- 2085US9824182B2Method and system for determining whether a drug will be effective on a patient with a diseaseRÖDER HEINRICH·Filed 2010·Granted Nov 21, 2017·7 cites·1 claims
- 2179US11150238B2Method for identification of cancer patients with durable benefit from immunotherapy in overall poor prognosis subgroupsBIODESIX INC·Filed 2018·Granted Oct 19, 2021·1 cites·8 claims
- 2274US11621057B2Classifier generation methods and predictive test for ovarian cancer patient prognosis under platinum chemotherapyBIODESIX INC·Filed 2017·Granted Apr 4, 2023·1 cites·11 claims
- 2370US12230398B2Predictive test for patient benefit from antibody drug blocking ligand activation of the T-cell programmed cell death 1 (PD-1) checkpoint protein and classifier development methodsBIODESIX INC·Filed 2020·Granted Feb 18, 2025·0 cites·7 claims
- 2469US2022026416A1Method for identification of cancer patients with durable benefit from immunotehrapy in overall poor prognosis subgroupsBIODESIX INC·Filed 2021·Application pending·0 cites
- 2560US2012191370A1Method and system for determining whether a drug will be effective on a patient with a diseaseRODER HEINRICH·Filed 2012·Application pending·0 cites
- 2659US2014200825A1Method for predicting whether a cancer patient will not benefit from platinum-based chemotherapy agentsBIODESIX INC·Filed 2014·Application pending·0 cites
- 2757US2014284468A1Cancer patient selection for administration of therapeutic agents using mass spectral analysis of blood-based samplesBIODESIX INC·Filed 2014·Application pending·0 cites
- 2850US2011208433A1Cancer patient selection for administration of therapeutic agents using mass spectral analysis of blood-based samplesBIODESIX INC·Filed 2011·Application pending·0 cites
- 2940US2015285817A1Method for treating and identifying lung cancer patients likely to benefit from EGFR inhibitor and a monoclonal antibody HGF inhibitor combination therapyBIODESIX INC·Filed 2015·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →